

Exploring Online Access of an Immuno-Oncology Wallet Card among Oncology Providers



Abstract #93

Janelle Schrag, MPH; Latha Shivakumar, PhD, CHCP; Monique Dawkins, EdD, MPA; Lorna Lucas, MSM; Leigh Boehmer, PharmD, BCOP

BACKGROUND

In 2019, the Association of Community Cancer Centers (ACCC) developed an immuno-oncology (IO) wallet card to address the continuous need for immune-related adverse event education and resources, particularly for IO patients and the non-oncology providers from whom they receive care. The wallet card was distributed to ACCC's membership of cancer programs via mailings and online, which included a short survey for users to complete at time of download. Specifically, the survey included demographic questions, as well as two questions about reason for download and existing patient resources.

To better understand member needs, as well as improve IO educational resources, ACCC investigated the demographics and motivations of individuals who access the IO wallet card.

METHODS

An exploratory analysis was performed on data collected through the download survey. Data included the survey responses from all downloads between March and September 2019 (n=141), which was then cleaned to remove duplicates, incomplete responses, and responses from ACCC staff, international users, pharmaceutical representatives, consultants, and patients. Analysis was then performed on the resulting data set of downloads from US-based health care providers (n=86), representing 80 unique organizations.

ACKNOWLEDGEMENTS

Support for the development of the ACCC IO wallet card and this analysis was provided by Genentech, Inc.

AUTHOR CONTACT INFORMATION

Leigh Boehmer, PharmD, BCOP
Medical Director
Association of Community Cancer Centers
1801 Research Blvd, Ste 400, Rockville, MD 20850
lboehmer@accc-cancer.org

accc-cancer.org

These finding shed light on the primary audiences accessing the IO wallet card, how this resource may complement other IO patient education materials, and areas where additional education may be needed.

Going forward, IO wallet card dissemination or related education may need to be tailored to better reach specific oncology disciplines (e.g., APPs) as well as those practicing in smaller clinics (e.g., freestanding cancer centers).


- Cancer program administrators and nurses accounted for the majority of downloads.
- Nearly half of those downloading the wallet card practiced in comprehensive community cancer programs.
- Survey responses indicated that the majority of downloads were due to the cancer program not already having the resource.
- Patient education materials provided by these institutions included wallet cards, as well as print materials developed by the cancer program, another professional organization, or distributed by drug companies.

Check out the wallet card!












- Cancer Program Administration, Leadership, or Business Operations (30%)
- Nurse (29%)
- Other Multidisciplinary Cancer Program Staff (9%)
- Patient Navigator (9%)
- Oncologist (7%)
- Advance Practice Provider (7%)
- Pharmacist (6%)
- Research/Academia (2%)




"I'm downloading this because..."

- My cancer program doesn't have this resource (47%)
- No Response (17%)


ATIONS

- I want to compare it with the IO wallet card developed by our cancer program (15%)
- Other or none of the above (10%)
- I want to compare it with the IO wallet card from another organization or drug company (10%)



Program Type

- Comprehensive community cancer program (44%)
- NCI-Designated Comprehensive Cancer Program (16%)
- Community Cancer Program (12%)
- Academic Comprehensive Cancer Program (9%)
- Physician Practice (other) (6%)
- Integrated Network Program (3%)
- Physician-Owned Oncology Practice (3%)
- Unknown (3%)
- Freestanding Cancer Center (2%)



"For IO patients, my cancer program provides..."

- Immunotherapy wallet cards (45%)
- Print materials developed by our cancer program (16%)
- Other or none of the above (14%)
- No Response (13%)
- Print materials developed by another professional org. (7%)
- Print materials distributed by drug companies (5%)